Ovagen

Ovagen is a synthetic tripeptide (Glu-Asp-Leu) from the Khavinson bioregulator family, researched for hepatic-tissue-targeted bioregulation, liver function, and hepatocyte protein synthesis. Despite the name suggesting an ovarian target, the Khavinson group designates Ovagen as a liver-targeted bioregulator. It is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Ovagen and how does the hepatic bioregulatory mechanism work?

Ovagen is a synthetic Glu-Asp-Leu tripeptide proposed to enter hepatocyte nuclei and modulate gene expression in pathways related to hepatic protein synthesis, liver regeneration, and hepatocellular function. Within the Khavinson framework, Ovagen is the liver-targeted complement to organ-specific bioregulators like Cardiogen (cardiac) and Pancragen (pancreatic). A hepatic (liver/GI) target is Ovagen's designation within the Khavinson framework; specific Ovagen effect data — hepatic protein synthesis, liver-injury recovery — is sparse in the indexed literature, so the proposed mechanism is best read as a family-level hypothesis for this peptide rather than an independently established finding. For the framework itself, see the science of Khavinson bioregulators.

Evidence level: preclinical (rodent liver models); Khavinson-group research; independent replication limited

What does the research show for Ovagen?

Dedicated, independently replicated Ovagen efficacy data is not established in the searchable record as of August 2026; the compound's hepatic positioning rests on the Khavinson group's organ-peptide framework. No human trial has been conducted. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted.

Evidence level: preclinical (rodent); Khavinson-group research; FDA-grade Phase 2/3 not conducted

How does Ovagen compare to other Khavinson peptide bioregulators?

Ovagen sits in the visceral-organ-targeting subset of the Khavinson cluster, alongside Pancragen (pancreatic), Prostamax (prostate), and Testagen (testicular).

What are the documented side effects of Ovagen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Ovagen?

Ovagen is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Ovagen is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Ovagen vendor verification matter?

Ovagen's name is sometimes confusingly conflated with ovarian-targeting compounds despite its liver-targeted positioning in the published Khavinson literature. Identity verification via mass spectrometry confirms the Glu-Asp-Leu sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Ovagen vendors?

Peptigrity collects independent third-party Certificates of Analysis for Ovagen from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Ovagen do?

Ovagen is proposed to act on hepatic (liver) tissue through epigenetic gene-expression modulation, with preclinical research focused on hepatocyte function and liver recovery markers. Human Phase 2/3 efficacy is not established at Western clinical standards.

Is Ovagen for the liver or ovaries?

Despite the name suggesting an ovarian target, the Khavinson group designates Ovagen as a liver-targeted bioregulator. The naming convention in the Khavinson cluster sometimes reflects historical research-program designations rather than transparent organ targeting.

Is Ovagen legal to purchase?

Ovagen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Ovagen be FDA-approved?

No active FDA approval pathway exists for Ovagen as of August 2026.

How can I verify an Ovagen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an Ovagen dose?

No. Ovagen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Ovagen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.